MET and non-small cell lung carcinoma: MET inhibitors like crizotinib have demonstrated significant clinical benefits in non-small cell lung cancer (NSCLC), particularly in patients with MET exon 14 skipping mutations(METΔ14) and high-level MET amplification (7).